Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ankyrin repeat domain 18F, pseudogene (ANKRD18FP) is classified as a pseudogene, meaning that it resembles a protein-coding gene but does not itself encode a functional protein[5][7]. Pseudogenes are typically generated from gene duplication or retrotransposition events that accumulate disabling mutations over time, leading to a loss of protein-coding capability. Although pseudogenes have historically been considered non-functional genomic relics (“junk DNA”), research indicates that some pseudogenes can influence the function and regulation of related protein-coding genes, often through transcriptional or post-transcriptional mechanisms such as serving as competing endogenous RNAs or producing regulatory non-coding RNAs[4]. There is currently no evidence to suggest that ANKRD18FP itself acts as a therapeutic target, receptor, or enzyme, nor that it is directly implicated in specific disease processes, interacts with drugs, or serves as a biomarker[5][6]. The precise biological function, if any, of ANKRD18FP has not been established.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ankyrin repeat domain 18F, pseudogene (ANKRD18FP).